Shaohan Yin

INTRODUCTION The PACIFIC trial established concurrent chemoradiotherapy (CCRT) followed by consolidative immunotherapy (CIT) as the standard of care for unresectable locally advanced non–small cell lung cancer (LA-NSCLC), yet 70% of patients still experience disease progression, with intrathoracic relapses dominating failure patterns.1, 2 Efforts to enhance CCRT efficacy, such as dose escalation tested in RTOG 0617, paradoxically worsened outcomes due to heightened toxicity.3 This setback...

Key Words Gastric cancer Dual-layer spectral CT Clinical-radiomic model Pathological T4 prediction Nomogram INTRODUCTION Gastric cancer (GC) is one of the most prevalent malignancies worldwide, ranked fifth in incidence and fourth in mortality (1). For locally advanced GC, neoadjuvant or perioperative chemotherapy has become the standard treatment approach (2,3).